GlassScriptPhysician profile
Rehan A Khan
NPI 1134104284
$2,592.30
in general payments reported to CMS, 2019-2025
28 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $155 · 2021: $480 · 2022: $394 · 2023: $247 · 2024: $370 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $375.14 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $249.98 | 2022 | |
| Indivior INC. | $249.62 | 2019-2023 | Sublocade |
| Lilly USA, LLC | $241.80 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $174.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $134.93 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $126.60 | 2019-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $124.97 | 2024 | Voquezna |
| Abbvie INC. | $109.11 | 2022-2025 | |
| Amarin Pharma, INC. | $101.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.43 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $81.63 | 2019-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $80.43 | 2021 | |
| Orexo US, INC. | $63.78 | 2019-2023 | Zubsolv |
| Dexcom, INC. | $58.07 | 2024-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $55.81 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.80 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $27.94 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $25.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2024 | |
| Exact Sciences Corporation | $18.39 | 2025 | Cologuard Collection Kit |
| Alvogen INC | $17.61 | 2023 | Teriparatide |
| Alkermes, INC. | $17.43 | 2020 | |
| Allergan, INC. | $17.15 | 2019 | |
| Astellas Pharma US INC | $16.62 | 2019 | |
| Ibsa Pharma INC. | $14.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.